Exploring Telitacicept in a patient with Pemphigus Vulgaris

Our case demonstrates significant improvement in autoantibody levels and clinical outcomes, suggesting telitacicept could be a alternative treatment for for mild pemphigus (PDAI ＞9) patients who is not recommended for RTX (PDAI ＜15), especially for those unresponsive to conventional treatments or with resistant scalp lesions in pemphigus.